Combining immune checkpoint inhibitors with immune factor antagonists (CD40, CD137, CD134, CD357) has demonstrated some synergistic benefits in the treatment of advanced melanoma in clinical studies (Wei et al., 2013). This evidence concerns the gene TNFRSF9 and melanoma.